Daiichi Sankyo (DSNKY.US) Latest Stock News - Major News Analysis

Event Tracking

Dec18

EMA Validates DATROWAY Marketing Authorization Application

07:32

Dec15

AstraZeneca and Daiichi Sankyo Receive FDA Approval for ENHERTU® in Combination with Pertuzumab for First-Line Treatment of HER2-Positive Breast Cancer

21:57

AstraZeneca's Enhertu Approved for First-Line HER2-Positive Metastatic Breast Cancer Treatment

20:38

FDA Approves Daiichi Sankyo and Roche's Combined Therapy for First-Line Treatment of Breast Cancer

18:41

Lunit Inc Announces Partnership with Daiichi Sankyo for AI-based Biomarker Research

16:05

Dec9

Daiichi Sankyo Launches Phase III Clinical Trial of ENHERTU® for Ovarian Cancer Efficacy Evaluation

12:01

Schedules & Filings

Schedules

Filings

Jan30

Earning Release(EST)

FY2026 Q3 Earning Release

Oct31

Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 3.369 B, Net Income 304.88 M, EPS 0.1646

Sep30

Distribution Plan(EST)

Cash dividend 0.2698 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change